CClinicalTrials.gg
TerminatedNCT03955887PNEUMOCHONDRIEUpdated Feb 3, 2026

Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation.

An observational study in Lung Diseases, Mechanical Ventilation and Bronchoalveolar Lavage, sponsored by Centre Hospitalier Universitaire Dijon. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

Why this study was terminated
technical difficulties
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
28
Ages
18 Years and older
Sex
All
01

Study summary

Sepsis leads to a deregulated host response that can lead to organ failure. During sepsis, experimental and clinical data suggest the occurrence of mitochondrial dysfunctions, particularly in circulating muscle and monocytes, which may contribute to organ failure and death.

Lower respiratory infection is the leading cause of death from infectious causes. Mechanical ventilation (MV) is required in 20% of cases of bacterial pneumopathy with Streptococcus pneumoniae (S.p.) , with mortality reaching 50%. There are then frequently criteria for acute respiratory distress syndrome (ARDS), combining bilateral lung involvement and marked hypoxemia.

Cyclic stretching of lung cells induced by MV causes sterile inflammation and tissue damage (i.e. ventilator-induced lung injury [VILI]), which can cause cellular dysfunction that alter the immune response, particularly during ARDS. This is why the application of a so-called protective MV is then required. However, this does not prevent about one-third of patients from showing signs of alveolar overdistension, as evidenced by an increase in motor pressure (MP) (MP≥ 15 cmH2O), associated with an increase in mortality.

The deleterious effects of MV could be explained by the occurrence of mitochondrial abnormalities. Indeed, the cyclic stretching of lung cells leads to dysfunction in the respiratory chain and the production of free oxygen radicals (FOS), altering membrane permeability. These phenomena could promote VILI, facilitate the translocation of bacteria from the lung to the systemic compartment and lead to alterations in immune response.

In our model of S.p. pneumopathy in rabbits, animals on MV develop more severe lung disorders (lack of pulmonary clearance of bacteria, bacterial translocation in the blood, excess mortality), compared to animals on spontaneous ventilation (SV). Intracellular pulmonary mitochondrial DNA (mtDNA) concentrations, a reflection of the mitochondrial pool, are significantly decreased in ventilated rabbits compared to SV rabbits and in infected rabbits compared to uninfected rabbits. At the same time, the mitochondrial content of circulating cells decreased early (H8) in all infected rabbits, but was only restored in rabbits in SV, those who survived pneumonia (Blot et al, poster ECCMID 2015, submitted article). These data suggest an alteration in the mechanisms that restore mitochondrial homeostasis (mitochondrial biogenesis and mitophagy) during the dual infection/MV agression, which may explain the observed excess mortality. Other work by our team illustrates the importance of these phenomena by showing in a mouse model of polymicrobial infection that inhibition of mitophagia in macrophages promotes survival (Patoli et al, in preparation). Human data on this subject are non-existent.

The phenomena of mitochondrial dysfunction nevertheless deserve to be explored in humans during the combined MV/pneumopathy aggression in order to understand its possible impact on the effectiveness of the host's immune response. In a personalized medicine approach, these data would open up prospects for targeted therapies, capable of activating mitochondrial biogenesis and/or modulating mitophagia, to prevent organ dysfunction and mortality during severe CALs treated with antibiotic therapy.

02

Conditions studied

  • Lung Diseases
  • Mechanical Ventilation
  • Bronchoalveolar Lavage

Browse trials for

03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 28 is below the median of 157 across 929 observational studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admited in the Intensive Care Unit and the Pneumology Intensive Care Unit of the CHU Dijon Bourgogne

Inclusion criteria

  • Patient who has given his non-opposition (or non-opposition obtained from close relative of ventilated patients, who will be informed as soon as possible).
  • Adult patient
  • Group 1: patient with:

    • Acute pneumonitis defined by: Signs and acute symptoms of pneumonia (new or worsening within the last 7 days), at least 2 of which are:

      • Coughing
      • Purulent sputum
      • Dyspnea
      • Chest pain
      • Temperature \< 35°C or ≥ 38°C And a new pulmonary radiological infiltrate (x-ray or CT scan on admission)
    • Not acquired under mechanical ventilation
    • Complicated from ARDS according to the new Berlin definition, Chest x-ray finding bilateral parenchymal opacities not fully explained by pleural effusions, nodules or atelectasis. Respiratory distress not explained by cardiac dysfunction or overfilling. An echocardiogram will be performed in case of diagnostic uncertainty. PaO2/FiO2 report \< 300 and PEP ≥ 5 cmH2O
    • Requiring the use of MV.
    • With a diagnostic BAL performed within 72 hours of the start of the MV
  • Group 2: Patients:

    • No fever during the last 15 days (reported or measured ≥ 37.8°C).
    • Not under MV,
    • Undergoing BAL for a reason other than acute infection (e.g. chronic interstitial syndrome, nodule or lung mass).

Exclusion criteria

Exclusion Criteria:

  • Patient not affiliated to the national health insurance system
  • Major under judicial protection
  • Pregnant, parturient or breastfeeding woman
  • Known primary or secondary immune deficiency (radiotherapy, chemotherapy, immunosuppressive therapy or systemic corticosteroid therapy (>10mg/day prednisone equivalent for more than 7 days) within 6 months before inclusion, HIV infection, primary cellular immune deficiency)
  • Patients with treatment known to modulate mitochondrial function, biogenesis and/or mitophagia (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, metformin, sildenafil)
  • Patients with pulmonary fibrosis or cystic fibrosis known to be associated with mitochondrial alterations
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
28 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Experimental

    Patients with severe acute lung disease requiring mechanical ventilation

    Biological: bronchoalveolar lavage fluid (BAL) · Biological: Venous blood

  • Control

    Patients receiving routine bronchoalveolar lavage for a pathology not suspected of acute infection

    Biological: bronchoalveolar lavage fluid (BAL) · Biological: Venous blood

Interventions

  • Biologicalbronchoalveolar lavage fluid (BAL)

    Recovery of a 10 mL volume of BAL fluid, performed as part of patient care

  • BiologicalVenous blood

    Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care

06

What researchers measure

Primary outcomes

  1. Active mitochondria content of alveolar macrophages

    Time frame: Through study completion, an average of 19 months

07

Study locations

1 site
  • Chu Dijon Bourogne
    Dijon, 21000, France
08

References and documents

Publications

  • Blot M, Bour JB, Quenot JP, Bourredjem A, Nguyen M, Guy J, Monier S, Georges M, Large A, Dargent A, Guilhem A, Mouries-Martin S, Barben J, Bouhemad B, Charles PE, Chavanet P, Binquet C, Piroth L; LYMPHONIE study group. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. J Transl Med. 2020 Dec 3;18(1):457. doi: 10.1186/s12967-020-02646-9. PubMed 33272291 ↗
  • Blot M, Jacquier M, Aho Glele LS, Beltramo G, Nguyen M, Bonniaud P, Prin S, Andreu P, Bouhemad B, Bour JB, Binquet C, Piroth L, Pais de Barros JP, Masson D, Quenot JP, Charles PE; Pneumochondrie study group. CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS. Crit Care. 2020 Nov 2;24(1):632. doi: 10.1186/s13054-020-03328-0. PubMed 33138839 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03955887
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
May 20, 2019
Start date
Jun 11, 2019
Primary completion
May 7, 2020
Completion
May 7, 2020
Last update
Feb 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion